Press release content from Business Wire. The AP news staff was not involved in its creation.
Global Duchenne Muscular Dystrophy Epidemiology and Patient Flow Report 2021 - ResearchAndMarkets.com
May 5, 2021 GMT
DUBLIN (BUSINESS WIRE) May 5, 2021
Global Duchenne Muscular Dystrophy Epidemiology and Patient Flow Analysis - 2021, provides Duchenne Muscular Dystrophy epidemiology, demographics, and patient flow. The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.
The research provides population data to characterize Duchenne Muscular Dystrophy patients, history of the disease at the population level (Duchenne Muscular Dystrophy prevalence, Duchenne Muscular Dystrophy incidence) and at the clinical level (from diagnosis to treated patients). It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.
Share:
ResearchAndMarkets.com s offering.
Global Epidermolysis Bullosa Epidemiology and Patient Flow Analysis - 2021, provides Epidermolysis Bullosa epidemiology, demographics, and patient flow. The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.
The research provides population data to characterize Epidermolysis Bullosa patients, history of the disease at the population level (Epidermolysis Bullosa prevalence, Epidermolysis Bullosa incidence) and at the clinical level (from diagnosis to treated patients). It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.
Research scope:
Countries: US, Germany, France, Italy, Spain, UK, Japan, G7 Countries
Press release content from Business Wire. The AP news staff was not involved in its creation.
Global Myasthenia Gravis Epidemiology and Patient Flow Report 2020-2035 - ResearchAndMarkets.com
May 5, 2021 GMT
DUBLIN (BUSINESS WIRE) May 5, 2021
Global Myasthenia Gravis Epidemiology and Patient Flow Analysis - 2021, provides Myasthenia Gravis epidemiology, demographics, and patient flow. The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.
The research provides population data to characterize Myasthenia Gravis patients, history of the disease at the population level (Myasthenia Gravis prevalence, Myasthenia Gravis incidence) and at the clinical level (from diagnosis to treated patients). It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.